A detailed history of Cubist Systematic Strategies, LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 49,081 shares of AMLX stock, worth $259,638. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,081
Previous 166,548 70.53%
Holding current value
$259,638
Previous $316,000 49.68%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.65 - $3.24 $193,820 - $380,593
-117,467 Reduced 70.53%
49,081 $159,000
Q2 2024

Aug 14, 2024

SELL
$1.62 - $2.71 $15,496 - $25,923
-9,566 Reduced 5.43%
166,548 $316,000
Q1 2024

May 15, 2024

SELL
$2.71 - $19.57 $706,553 - $5.1 Million
-260,721 Reduced 59.68%
176,114 $500,000
Q4 2023

Feb 14, 2024

BUY
$12.07 - $18.46 $2.86 Million - $4.37 Million
236,645 Added 118.21%
436,835 $6.43 Million
Q3 2023

Nov 14, 2023

BUY
$18.08 - $23.45 $2.64 Million - $3.42 Million
145,942 Added 269.03%
200,190 $3.67 Million
Q2 2023

Aug 14, 2023

SELL
$20.98 - $31.42 $204,555 - $306,345
-9,750 Reduced 15.23%
54,248 $1.17 Million
Q1 2023

May 15, 2023

BUY
$27.71 - $40.93 $1.67 Million - $2.46 Million
60,192 Added 1581.5%
63,998 $1.88 Million
Q4 2022

Feb 14, 2023

SELL
$29.75 - $39.26 $8,865 - $11,699
-298 Reduced 7.26%
3,806 $140,000
Q3 2022

Nov 14, 2022

SELL
$17.15 - $30.92 $838,566 - $1.51 Million
-48,896 Reduced 92.26%
4,104 $116,000
Q2 2022

Aug 15, 2022

BUY
$6.85 - $19.93 $123,889 - $360,453
18,086 Added 51.8%
53,000 $1.02 Million
Q1 2022

May 16, 2022

BUY
$12.85 - $32.9 $448,644 - $1.15 Million
34,914 New
34,914 $449,000

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $310M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.